ConductScience.org, home

Paper39286286

Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation.

Lu W and 5 others. Drug Des Devel Ther, 2024. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation. Papers, record 39286286. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39286286

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation.
PubMed
Journal
Drug Des Devel Ther
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
2.21, provisional
iCite
Revised in PubMed
2024-09-18
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lu WWeihttps://orcid.org/0000-0001-5396-4004
2Yang ZZhenyuhttps://orcid.org/0000-0001-6151-8151
3Wang MMengjie
4Zhang YYe
5Qi ZZuoliang
6Yang XXiaonanhttps://orcid.org/0000-0002-3353-6982

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
HemangiomaMajor topic
Cell ProliferationMajor topic
Drug Screening Assays, AntitumorMajor topic
Humans
Infant
Computer Simulation
Apoptosis
Protein Interaction Maps
Drug Repositioning
Dose-Response Relationship, Drug

Source PubMed

Download CSV of topics

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129130882Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data.Elife2017https://conductscience.org/library/papers/29130882PubMed
229609830Safety data and withdrawal of hepatotoxic drugs.Therapie2021https://conductscience.org/library/papers/29609830PubMed
330470818Turning foes to friends: targeting cancer-associated fibroblasts.Nat Rev Drug Discov2019https://conductscience.org/library/papers/30470818PubMed
418676554Growth characteristics of infantile hemangiomas: implications for management.Pediatrics2008https://conductscience.org/library/papers/18676554PubMed
530127393Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.Nat Med2018https://conductscience.org/library/papers/30127393PubMed
616950977Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment.Pediatrics2006https://conductscience.org/library/papers/16950977PubMed
716199517Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.Proc Natl Acad Sci U S A2005https://conductscience.org/library/papers/16199517PubMed
833961406Using Rotenone to Model Parkinson's Disease in Mice: A Review of the Role of Pharmacokinetics.Chem Res Toxicol2021https://conductscience.org/library/papers/33961406PubMed
932662682β-blocker therapy for infantile hemangioma.Expert Rev Clin Pharmacol2020https://conductscience.org/library/papers/32662682PubMed
1023199362MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study.J Cardiovasc Magn Reson2012https://conductscience.org/library/papers/23199362PubMed
1121995808A prospective study of infantile hemangiomas with a focus on incidence and risk factors.Pediatr Dermatol2011https://conductscience.org/library/papers/21995808PubMed
126203733Drug-induced pulmonary fibrosis.Environ Health Perspect1984https://conductscience.org/library/papers/6203733PubMed
1318852116Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther2008https://conductscience.org/library/papers/18852116PubMed
144122362A clinical review of bleomycin--a new antineoplastic agent.Cancer1973https://conductscience.org/library/papers/4122362PubMed
1525521941cytoHubba: identifying hub objects and sub-networks from complex interactome.BMC Syst Biol2014https://conductscience.org/library/papers/25521941PubMed
1625352553STRING v10: protein-protein interaction networks, integrated over the tree of life.Nucleic Acids Res2015https://conductscience.org/library/papers/25352553PubMed
1730425336mTOR signalling and cellular metabolism are mutual determinants in cancer.Nat Rev Cancer2018https://conductscience.org/library/papers/30425336PubMed
1833068428Comparative Toxicogenomics Database (CTD): update 2021.Nucleic Acids Res2021https://conductscience.org/library/papers/33068428PubMed
1923701395Haemangioma: clinical course, complications and management.Br J Dermatol2013https://conductscience.org/library/papers/23701395PubMed
2022455463clusterProfiler: an R package for comparing biological themes among gene clusters.OMICS2012https://conductscience.org/library/papers/22455463PubMed

See all 47 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42105055Therapies for Infantile Haemangiomas: Current Practice and Evolving Perspectives.Dermatol Ther (Heidelb)2026https://conductscience.org/library/papers/42105055PubMed
41928438Targeted Therapies in Infantile Hemangiomas and Vascular Malformations: From β-Blockers to PI3K/AKT/mTOR Inhibitors.J Cell Mol Med2026https://conductscience.org/library/papers/41928438PubMed
41567426Topical propranolol for infantile hemangioma: a comprehensive review of mechanisms, clinical efficacy, and novel formulations.Front Pediatr2025https://conductscience.org/library/papers/41567426PubMed
41256263Propranolol (1 mg/kg/day) with intralesional bleomycin versus propranolol monotherapy for infantile hemangioma: a randomized controlled trial.Front Pharmacol2025https://conductscience.org/library/papers/41256263PubMed
41255770Machine learning identifies immune-perinatal predictors of infantile hemangioma.Front Pediatr2025https://conductscience.org/library/papers/41255770PubMed
40428263Vulvar Hemangioma: A Review.Diagnostics (Basel)2025https://conductscience.org/library/papers/40428263PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
PRKG15592PubTator's text mininghttps://conductscience.org/library/genes/5592NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39286286

GET https://conductscience.org/api/papers/v1/39286286/references?page=2